Generic drug manufacturers were the first in the biopharma sector to pursue the IPR process to invalidate a patent. Hedge fund manager Kyle Bass subsequently created a firestorm filing petitions against more than a dozen biopharma companies under the name Coalition for Affordable Drugs. Biosimilar sponsors have also begun using IPRs to get early rulings and avoid the patent dispute resolution process in the Biologics Price Competition and Innovation Act. Below are some of the petitions filed by these three groups.
Coalition for Affordable Drugs v. Celgene Corp.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?